Among patients with acute coronary syndromes referred for percutaneous intervention, bivalirudin did not lower rates of major adverse cardiovascular events or net adverse clinical outcomes as compared with unfractionated heparin.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content